TELA Bio Files 8-K on Operations and Financials

Ticker: TELA · Form: 8-K · Filed: Aug 11, 2025 · CIK: 1561921

Tela Bio, Inc. 8-K Filing Summary
FieldDetail
CompanyTela Bio, Inc. (TELA)
Form Type8-K
Filed DateAug 11, 2025
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financial-condition, operations

Related Tickers: TELA

TL;DR

TELA Bio dropped an 8-K on financials and ops - check it for the latest.

AI Summary

On August 11, 2025, TELA Bio, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with Regulation FD disclosures and financial statements. No specific financial figures or operational updates were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates TELA Bio is providing updates on its financial performance and operational status to the SEC, which is crucial for investors to assess the company's health.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting operational and financial information, without immediate indication of significant negative events.

Key Players & Entities

  • TELA Bio, Inc. (company) — Registrant
  • August 11, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • 45-5320061 (ein) — I.R.S. Employer Identification No.
  • 1 Great Valley Parkway, Suite 24 (address) — Address of principal executive offices
  • Malvern, Pennsylvania (location) — City and State of principal executive offices
  • 19355 (zip_code) — Zip code of principal executive offices
  • (484) 320-2930 (phone_number) — Registrant's telephone number

FAQ

What specific financial results or operational updates are being reported by TELA Bio, Inc. in this 8-K filing?

The provided excerpt of the 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' but does not detail specific financial figures or operational updates.

What is the exact date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is August 11, 2025.

In which state is TELA Bio, Inc. incorporated?

TELA Bio, Inc. is incorporated in Delaware.

What is the principal executive office address for TELA Bio, Inc.?

The principal executive office address is 1 Great Valley Parkway, Suite 24, Malvern, Pennsylvania 19355.

What is the SEC file number for TELA Bio, Inc.?

The SEC file number for TELA Bio, Inc. is 001-39130.

Filing Stats: 649 words · 3 min read · ~2 pages · Grade level 9.9 · Accepted 2025-08-11 16:06:04

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share TELA Nasdaq Global Market

Filing Documents

02

Item 2.02 Results of Operations and Financial Condition. On August 11, 2025, TELA Bio, Inc. (the " Company ") issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the " Securities Act "), or the Exchange Act, except as expressly set forth by specific reference in such filing.

01

Item 7.01 Regulation FD Disclosure. On August 11, 2025, the Company updated information reflected in a corporate slide deck, which representatives of the Company will use in various meetings with investors from time to time. A copy of the presentation is attached hereto as Exhibit 99.2, and incorporated herein by reference. The information furnished pursuant to Item 7.01, including Exhibit 99.2, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits The following exhibits are being furnished herewith: Exhibit No. Document 99.1 Press Release of TELA Bio, Inc., dated August 11, 2025. 99.2 Corporate Slide Deck, dated August 11, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELA BIO, INC. By: /s/ Antony Koblish Name: Antony Koblish Title: Chief Executive Officer and Director Date: August 11, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.